These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29404513)

  • 21. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.
    Yoneda M; Suzuki K; Kato S; Fujita K; Nozaki Y; Hosono K; Saito S; Nakajima A
    Radiology; 2010 Aug; 256(2):640-7. PubMed ID: 20529989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Appendectomy and Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Nakano M; Murohisa T; Imai Y; Tamano M; Hiraishi H
    Gastroenterology Res; 2013 Feb; 6(1):17-25. PubMed ID: 27785221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
    Cengiz M; Ozenirler S
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
    Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
    J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
    Wang Y; Vincent R; Yang J; Asgharpour A; Liang X; Idowu MO; Contos MJ; Daitya K; Siddiqui MS; Mirshahi F; Sanyal AJ
    Hepatology; 2017 Jun; 65(6):1891-1903. PubMed ID: 28133774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology.
    Murawaki Y; Ikuta Y; Koda M; Kawasaki H
    Hepatology; 1994 Oct; 20(4 Pt 1):780-7. PubMed ID: 7927217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Decaris ML; Li KW; Emson CL; Gatmaitan M; Liu S; Wang Y; Nyangau E; Colangelo M; Angel TE; Beysen C; Cui J; Hernandez C; Lazaro L; Brenner DA; Turner SM; Hellerstein MK; Loomba R
    Hepatology; 2017 Jan; 65(1):78-88. PubMed ID: 27706836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease.
    Seki K; Shima T; Oya H; Mitsumoto Y; Mizuno M; Okanoue T
    Hepatol Res; 2017 Aug; 47(9):882-889. PubMed ID: 27753194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins.
    Lucero D; Miksztowicz V; Gualano G; Longo C; Landeira G; Álvarez E; Zago V; Brites F; Berg G; Fassio E; Schreier L
    Clin Chim Acta; 2017 Oct; 473():1-8. PubMed ID: 28802640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
    Park GJ; Wiseman E; George J; Katelaris PH; Seow F; Fung C; Ngu MC
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1411-6. PubMed ID: 21557768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.
    Alkhouri N; Sedki E; Alisi A; Lopez R; Pinzani M; Feldstein AE; Nobili V
    Liver Int; 2013 Jan; 33(1):79-85. PubMed ID: 23146095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome.
    Huang Y; de Boer WB; Adams LA; MacQuillan G; Rossi E; Rigby P; Raftopoulos SC; Bulsara M; Jeffrey GP
    Liver Int; 2013 Sep; 33(8):1249-56. PubMed ID: 23617278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
    Ajmera V; Perito ER; Bass NM; Terrault NA; Yates KP; Gill R; Loomba R; Diehl AM; Aouizerat BE;
    Hepatology; 2017 Jan; 65(1):65-77. PubMed ID: 27532276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.